In its recent statement, Vertex Pharmaceuticals Inc. has declared that clinical results for their combination of cystic fibrosis drugs depart a noteworthy improvement in health of patients with cystic fibrosis. The company announced that the drugs have been able to improve the functioning of lungs of the patients.
It has been reported that it was this Thursday when final results of the mid-stage of the drug were released.
Previous reports suggest that it was early May, when the Cambridge based company issued an interim analysis reports, which included consequences of its Kalydeco therapy, which was given along with another experimental drug VX-809.
It has been recovered that the therapy is the foremost treatment until now, which targets the main cause behind the occurrence of the condition, which is rare and an autosomal recessive genetic disorder.
As a consequence, the shares of the company have shown a rise.
However, a few weeks past, the interim analysis reports were revised. The company said, “It overstated the clinical data. Between the initial report and the revision, several executives and company directors sold stock shares worth millions of dollars”.
However, a spokesman from the company affirmed that the results released this Thursday are the confirmed results.